Target intelligence / Profile preview

Ribosomal protein L21 pseudogene 131 (RPL21P131)

Target
RPL21P131
Molecular classification
Other (Processed pseudogene)
01

Overview

RPL21P131 (ribosomal protein L21 pseudogene 131) is a processed pseudogene derived from the ribosomal protein L21 gene (RPL21). While its sequence resembles the functional ribosomal protein L21 gene, RPL21P131 has accumulated mutations such that it cannot produce a functional protein. Pseudogenes like RPL21P131 are common in the human genome and typically do not perform biological roles nor serve as drug targets[2][8]. The functional ribosomal protein L21 (encoded by RPL21) is a protein component of the large (60S) ribosomal subunit, which participates in protein synthesis[3][5], but RPL21P131 itself does not encode a protein or participate in ribosome function or cellular pathways. RPL21P131 is not a therapeutic target, receptor, enzyme, transporter, or functional gene. The query may be incorrect if the intent was to identify a druggable protein or biomarker, as RPL21P131 is a pseudogene with no established function or clinical relevance.

Other names
RPL21_64_1647RPL21P131
02

Mechanism of action

None; pseudogenes are not targeted by drugs for a mechanism of action

03

Biological functions

None; pseudogenes do not encode functional proteins and are typically transcriptionally inactive or non-functional
04

Disease associations

None; there is no evidence that this pseudogene plays a direct role in disease
05

Safety considerations

None; pseudogenes are generally not relevant for safety or therapeutic interventions
06

Interacting drugs

None; there are no drugs known to interact with this pseudogene
07

Biomarkers

None; RPL21P131 is not used as a biomarker

Beyond the preview

Go deeper on Ribosomal protein L21 pseudogene 131 (RPL21P131).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L21 pseudogene 131 (RPL21P131).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call